DAEJEON, South Korea, July 3 /PRNewswire/ --

Panagene today announced that it has licensed the right to sell PNA
monomers from the Copenhagen Inventor Group (CIG) effective 1st June 2007.
The agreement allows Panagene to synthesize, manufacture and sell peptide
nucleic acids (PNA) monomers for use by researchers. Panagene had previously
obtained exclusive worldwide license under CIG's patents to PNA custom
synthesis ( http://www.prnewswire.co.uk/cgi/news/release?id=176764 ).

"Panagene has shown a tremendous commitment to PNA research and we are
very happy to have granted them a license to commercialize PNA monomers,"
said Peter Nielsen, Ph.D., Professor of Molecular Biology at the University
of Copenhagen, Denmark and co-inventor of PNA. "Ready availability of high
quality PNA monomers from Panagene will benefit everyone in the field,"
continued Dr. Nielsen whose laboratory is still actively engaged in PNA
research.

"Panagene is committed to bringing high quality PNA monomers to
scientists all over the world," said Sung Kee Kim, Ph.D., President and Chief
Executive Officer of Panagene. "This license from CIG in addition to the
custom PNA synthesis license already granted shows our continued commitment
to expand the field of PNA research," continued Dr. Kim. "Our customers can
expect the same high quality PNA monomers as our oligomers. The monomers are
available now," said Wonyong Koh, Ph.D., Vice President of Panagene in charge
of Global Marketing.

PNA are mimics of DNA with unique properties that confer advantages in
many applications. Panagene estimates the PNA market today to be
approximately 5% of DNA/ RNA synthesis market but with this license strongly
believes that it will be able to grow this significantly. Researchers
interested in obtaining PNA monomer and custom PNA can do so through
http://www.panagene.com .

About Panagene:

Panagene provides products and services that support academic, government
research institutions, pharmaceutical, and biotech companies worldwide in
their PNA research efforts. The PNA technology is used in life science
research, diagnostics and in therapeutics. Panagene's own research and
development efforts are focused on breakthrough innovation not only in
chemical synthesis and manufacturing of PNA oligomers, but also in PNA array
and diagnostics. Founded in 2001, Panagene is headquartered in Daejeon, South
Korea, and conducts business around the world. For more information, visit
http://www.panagene.com .

For further information, contact:

     Dr. Wonyong Koh
     Tel: +82-42-861-9295 (Asia and Europe)
     Email: wykoh@panagene.com

     Dr. Ravi Vinayak:
     Tel: +1-650-996-4951 (Americas)
     Email: ravi.vinayak@newtrailconsulting.com



Web site: http://www.panagene.com